Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.60 |
| ▸ | MELK | Q14680 | 3/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529171 | 1.00 | MAPK1 (0.61) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL530507 | 0.90 | MAPK1 (0.63) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL529026 | 0.90 | MAPK1 (0.63) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL529027 | 0.90 | MAPK1 (0.63) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL529812 | 0.89 | MAPK1 (0.64) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL529813 | 0.89 | MAPK1 (0.64) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL18843746 | 0.89 | MAPK1 (0.66) | MAPK1DYRK1ARXFP1GAANPSR1 | |
| SCHEMBL17272569 | 0.89 | MAPK1 (0.66) | MAPK1DYRK1ARXFP1GAANPSR1 | |
| SCHEMBL20515220 | 0.89 | MAPK1 (0.63) | MAPK1DYRK1AMELKRXFP1GAA | |
| SCHEMBL18843693 | 0.89 | MAPK1 (0.63) | MAPK1DYRK1AMELKRXFP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | MAPK1 537/4885DYRK1A 1633/4885MELK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.